http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006004945-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26d3a5de6abddb505902d165f7ee6d87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65a99022c5d223ffc1707bc388c8dcee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e32d36ac6d35aea8725985b6e845bf9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47c7fb467094fd87bf762984178de5a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5821ad31444e4d8f4492fa50489225e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_606a9b14fe1e9993f275b590378b8a2a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
filingDate 2005-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e35b7ee12099f4c475a06540192315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79c2d567beb0ba03e66eba741c8a3c28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23a104bc10f366480703f222e58d3da8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0ed1de2e0d76019c6e581bdc11b6abb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bce22625ff20c9d6e7d92e3ccb5b355
publicationDate 2006-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006004945-B1
titleOfInvention Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
abstract The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.
priorityDate 2004-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399399
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457521263
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6212
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578614
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413689170
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408088710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393705
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393368
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5558
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134664
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419567920
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393640
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119440

Total number of triples: 45.